Journal of Surgical Oncology 44:252-255 (1990)
Adjuvant Chemotherapy and Scar Irradiation in Breast Cancer FlKRl ICLI, MD, DILEK DINCOL, MD, ERDOGAN ISIKMAN, MD, AND MUTTALIP UNAL, MD From the Medical Oncology Section (F.I., D.DJ, Radiation Oncology Section (E.I.), and Department of Surgery (M.U.), University of Ankara Medical School, Ankara, Turkey
Twenty-three consecutive premenopausal patients with breast cancer who had four or more positive axillary nodes were treated with six cycles of CMFP followed by irradiation limited to the mastectomy scar (CT-SRT). The relapse-free survival (RFS) rate was compared with a group of 15 patients who were treated with chemotherapy alone (CT). Following an average follow-up of 30 months, the relapse rates for the CT-SRT and CT groups were 30.4% vs. 73.2%, respectively (P
Adjuvant Chemotherapy and Scar Irradiation in Breast Cancer FlKRl ICLI, MD, DILEK DINCOL, MD, ERDOGAN ISIKMAN, MD, AND MUTTALIP UNAL, MD From the Medical Oncology Section (F.I., D.DJ, Radiation Oncology Section (E.I.), and Department of Surgery (M.U.), University of Ankara Medical School, Ankara, Turkey
Twenty-three consecutive premenopausal patients with breast cancer who had four or more positive axillary nodes were treated with six cycles of CMFP followed by irradiation limited to the mastectomy scar (CT-SRT). The relapse-free survival (RFS) rate was compared with a group of 15 patients who were treated with chemotherapy alone (CT). Following an average follow-up of 30 months, the relapse rates for the CT-SRT and CT groups were 30.4% vs. 73.2%, respectively (P
